This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inter Parfums (IPAR) Withdraws 2020 View Due to Coronavirus
by Zacks Equity Research
Due to the coronavirus outbreak and its impact on revenues and costs, Inter Parfums (IPAR) has withdrawn full-year 2020 guidance.
Ulta Beauty Enhances Financial Flexibility Amid Coronavirus
by Zacks Equity Research
Ulta Beauty (ULTA) announces that it has drawn down $800 million under its revolving credit facility in order to maintain financial flexibility amid the coronavirus outbreak.
Why Is Nu Skin (NUS) Down 37.4% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Nu Skin Mainland China Woes Worsen Due to Coronavirus?
by Zacks Equity Research
Nu Skin (NUS) anticipates sales in Mainland China to decline 20-25% in 2020. The company puts meetings on hold in the region due to the coronavirus outbreak.
Coronavirus Steals Glitter Off These 3 Cosmetic Stocks
by Vrishali Bagree
Coronavirus-led worries weigh on the guidance of these cosmetic stocks due to reduced global travel and sluggish traffic.
Nu Skin's (NUS) Q4 Earnings Meet Estimates, Down Year on Year
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2019 results reflect lower earnings and sales. Further, management expects the coronavirus outbreak to hurt Mainland China sales in 2020.
Here's How Nu Skin (NUS) is Placed Ahead of Q4 Earnings
by Zacks Equity Research
Impacts from foreign currency headwinds are likely to get reflected in Nu Skin's (NUS) fourth-quarter 2019 results. However, the company is on track with product launches and programs to bolster sales leaders.
Earnings Preview: Nu Skin Enterprises (NUS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nu Skin (NUS) Down 4.4% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin Plunges in 6 Months, Mainland China Woes Persist
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China thanks to increased scrutiny by the government. Also, management provides an unimpressive view for 2019.
Nu Skin's (NUS) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Nu Skin's (NUS) third-quarter earnings are affected by limited sales meetings in Mainland China.
Nu Skin Enterprises (NUS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 3.95% and -2.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's How Nu Skin (NUS) Looks Just Ahead of Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) third-quarter 2019 results are expected to reflect impacts of foreign currency headwinds.
Earnings Preview: Nu Skin Enterprises (NUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Estee Lauder Maintain Momentum on Solid Travel Retail?
by Zacks Equity Research
Estee Lauder's (EL) strong online business and travel retail network are likely to drive growth. The company also benefits from a solid presence in emerging markets.
NUS vs. IPAR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?
Avon's (AVP) Open Up Strategy to Drive Long-Term Growth
by Zacks Equity Research
Avon's (AVP) Open Up strategy keeps the company on track to attain its financial targets for 2021.
Nu Skin's Customer Base Bodes Well, Mainland China is a Worry
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China that led to an unimpressive view for 2019. However, a rising customer base bodes well.
Nu Skin Down 12% in 3 Months, Mainland China is a Concern
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China, stemming from the government's campaign to scrutinize offerings of direct selling and health products industries.
Nu Skin (NUS) Up 1.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Q2 Earnings In Line With Estimates, Sales Miss
by Zacks Equity Research
Headwinds in Mainland China were a drag on Nu Skin's (NUS) revenues and earnings in the second quarter of 2019.
Nu Skin Enterprises (NUS) Meets Q2 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 0.00% and -1.53%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Disappointment in Store for Nu Skin (NUS) Q2 Earnings?
by Zacks Equity Research
Nu Skin's (NUS) Q2 performance is likely to be hurt by the government campaign in Mainland China to inspect offerings of direct selling industries and health products.
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NUS or IPAR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?